Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-26b20b6a67265be2cf1102bb12c87943",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-26b20b6a67265be2cf1102bb12c87943",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-26b20b6a67265be2cf1102bb12c87943",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-26b20b6a67265be2cf1102bb12c87943\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-26b20b6a67265be2cf1102bb12c87943</b></p><a name=\"composition-en-26b20b6a67265be2cf1102bb12c87943\"> </a><a name=\"hccomposition-en-26b20b6a67265be2cf1102bb12c87943\"> </a><a name=\"composition-en-26b20b6a67265be2cf1102bb12c87943-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/11/711/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - matever</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/11/711/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp26b20b6a67265be2cf1102bb12c87943"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - matever",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Matever is and what it is used for</li><li>What you need to know before you take Matever</li><li>How to take Matever</li><li>Possible side effects</li><li>How to store Matever</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What matever is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What matever is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).</p><p>Matever is used:</p><ul><li>on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.</li><li>as an add-on to other antiepileptic medicines to treat: partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).</li></ul></div>"
}
},
{
"title" : "2. What you need to know before you take matever",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take matever"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Matever</p><ul><li>if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions<br/>Talk to your doctor before taking Matever</p><ul><li>If you suffer from kidney problems, follow your doctor s instructions. He/she may decide if your dose should be adjusted.</li><li>If you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor.</li><li>A small number of people being treated with anti-epileptics such as Matever have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.</li><li>If you have a family or medical history of irregular heart rhythm (visible on an electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.</li></ul><p>Tell your doctor or pharmacist if any of the following side effects gets serious or lasts longer than a few days:</p><ul><li>Abnormal thoughts, feeling irritable or reacting more aggressively than usually or if you or your family and friends notice important changes in mood or behaviour.</li><li>Aggravation of epilepsy Your seizures may rarely become worse or happen more often, mainly during the first month after the start of the treatment or increase of the dose. In a very rare form of early-onset epilepsy (epilepsy associated with SCN8A mutations) that causes multiple types of seizures and loss of skills you may notice that the seizures remain present or are becoming worse during your treatment.</li></ul><p>If you experience any of these new symptoms while taking Matever, see a doctor as soon as possible.</p><p>Children and adolescents</p><ul><li>Matever is not indicated in children and adolescents below 16 years on its own (monotherapy).</li></ul><p>Other medicines and Matever<br/>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Do not take macrogol (a medicine used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a loss of its effect.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. You should not stop your treatment without discussing this with your doctor. A risk of birth defects for your unborn child cannot be completely excluded.<br/>Breast-feeding is not recommended during treatment.</p><p>Driving and using machines Matever may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.</p><p>Matever 250 mg, 750 mg tablets contain Sunset Yellow FCF (E110)<br/>Sunset Yellow FCF (E110) colouring agent may cause allergic reactions. The other strengths of Matever tablets do not contain this ingredient.</p><p>Matever 1000 mg tablets contain lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The other strengths of Matever tablets do not contain this ingredient.</p></div>"
}
},
{
"title" : "3. How to take matever",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take matever"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Take the number of tablets following your doctor s instructions. Matever must be taken twice a day, once in the morning and once in the evening, at about the same time each day.</p><p>Adjunctive Therapy and monotherapy (from 16 years of age)</p><ul><li><p>Adults ( 18 years) and adolescents (12 to 17 years) weighing 50 kg or more: Recommended dose: between 1 000 mg and 3 000 mg each day. When you will first start taking Matever, your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest daily dose. Example: if your daily dose is intended to be 1 000 mg, your reduced starting dose is 1 tablet of 250 mg in the morning and 1 tablet of 250 mg in the evening, and the dose will be gradually incremented to reach 1 000 mg daily after 2 weeks.</p></li><li><p>Adolescents (12 to 17 years) weighing 50 kg or less: Your doctor will prescribe the most appropriate pharmaceutical form of Matever according to weight and dose.</p></li><li><p>Dose in infants (1 month to 23 months) and children (2 to 11 years) weighing less than kg: Your doctor will prescribe the most appropriate pharmaceutical form of Matever according to the age, weight and dose.</p></li></ul><p>Levetiracetam 100 mg/ml oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from 6 to 17 years) weighing less than 50 kg and when tablets don t allow accurate dose.</p><p>Method of administration Swallow Matever tablets with a sufficient quantity of liquid (e.g. a glass of water). You may take Matever with or without food. After oral administration the bitter taste of levetiracetam may be experienced.</p><p>Duration of treatment</p><ul><li>Matever is used as a chronic treatment. You should continue Matever treatment for as long as your doctor has told you.</li><li>Do not stop your treatment without your doctor s advice as this could increase your seizures.</li></ul><p>If you take more Matever than you should The possible side effects of an overdose of Matever are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma. Contact your doctor if you took more tablets than you should. Your doctor will establish the best possible treatment of overdose.</p><p>If you forget to take Matever Contact your doctor if you have missed one or more doses.<br/>Do not take a double dose to make up for a forgotten tablet.</p><p>If you stop taking Matever If stopping treatment Matever should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Matever treatment, he/she will instruct you about the gradual withdrawal of Matever.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately, or go to your nearest emergency department, if you experience:</p><ul><li>weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction</li><li>swelling of the face, lips, tongue and throat (Quincke s oedema)</li><li>flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])</li><li>symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function</li><li>a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)</li><li>a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)</li><li>a more severe form of rash causing skin peeling in more than 30 % of the body surface (toxic epidermal necrolysis)</li><li>signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.</li></ul><p>The most frequently reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.</p><p>Very common: may affect more than 1 in 10 people</p><ul><li>nasopharyngitis;</li><li>somnolence (sleepiness), headache.</li></ul><p>Common: may affect up to 1 in 10 people</p><ul><li>anorexia (loss of appetite);</li><li>depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;</li><li>convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);</li><li>vertigo (sensation of rotation);</li><li>cough;</li><li>abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;</li><li>rash;</li><li>asthenia/fatigue (tiredness).</li></ul><p>Uncommon: may affect up to 1 in 100 people</p><ul><li><p>decreased number of blood platelets, decreased number of white blood cells;</p></li><li><p>weight decrease, weight increase;</p></li><li><p>suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;</p></li><li><p>amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);</p></li><li><p>diplopia (double vision), vision blurred;</p></li><li><p>elevated/abnormal values in a liver function test;</p></li><li><p>hair loss, eczema, pruritus;</p></li><li><p>muscle weakness, myalgia (muscle pain);</p></li><li><p>injury.</p></li></ul><p>Rare: may affect up to 1 in 1 000 people</p><ul><li>infection;</li><li>decreased number of all blood cell types;</li><li>severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke s oedema [swelling of the face, lips, tongue and throat]);</li><li>decreased blood sodium concentration;</li><li>suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);</li><li>delirium;</li><li>encephalopathy (see sub-section Tell your doctor immediately for a detailed description of symptoms;</li><li>seizures may become worse or happen more often;</li><li>uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);</li><li>change of the heart rhythm (Electrocardiogram);</li><li>pancreatitis;</li><li>liver failure, hepatitis;</li><li>sudden decrease in kidney function;</li><li>skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);</li><li>rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</li><li>limp or difficulty walking.</li><li>combination of fever, muscle stiffness, unstable blood pressure and heart rate, confusion, low level of consciousness (may be signs of a disorder called neuroleptic malignant syndrome). Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</li></ul><p>Very rare: may affect up to 1 in 10 000 people</p><ul><li>repeated unwanted thoughts or sensations or the urge to do something over and over again (Obsessive Compulsive Disorder).</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store matever",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store matever"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton box and blister after EXP . The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Matever contains</p><p>The active substance is called levetiracetam.<br/>One tablet of Matever 250 mg contains 250 mg of levetiracetam. One tablet of Matever 500 mg contains 500 mg of levetiracetam. One tablet of Matever 750 mg contains 750 mg of levetiracetam. One tablet of Matever 1000 mg contains 1000 mg of levetiracetam.</p><p>The other ingredients are: Tablet core: calcium hydrogen phosphate dihydrate, cellulose microcrystalline, crospovidone type A, hydroxypropylcellulose (L).</p><p>250 mg: Film-coating: hypromellose (E464), titanium dioxide (E171), talc, propylene glycol (E1520) colourants*.</p><p>500 mg: Film-coating: hypromellose (E464), titanium dioxide (E171), hydroxypropyl cellulose (E463), propylene glycol (E1520), sorbic acid (E200), sorbitan monooleate (E494), vanillin, colourants*.</p><p>750 mg: Film-coating: hypromellose (E464), macrogol/PEG 4000, titanium dioxide (E171), colourants*.</p><p>1000 mg: Film-coating: hypromellose (E464), lactose monohydrate,macrogol/PEG 4000, titanium dioxide (E171).</p><ul><li>The colourants are: 250 mg tablet: indigo carmine aluminum lake (E132), sunset yellow FCF aluminum lake (E110), quinoline yellow aluminium lake (E104) 500 mg tablet: quinoline yellow aluminium lake (E104) 750 mg tablet: indigo carmine aluminum lake (E132), sunset yellow FCF aluminum lake (E110), iron oxide red (E172) 1000 mg tablet: (no additional colourant).</li></ul><p>What Matever looks like and contents of the pack</p><p>Matever 250 mg: The film-coated tablets are blue, oblong, biconvex. Matever 500 mg: The film-coated tablets are yellow, oblong, biconvex. Matever 750 mg: The film-coated tablets are pink, oblong, biconvex. Matever 1000 mg: The film-coated tablets are white, oblong, biconvex.</p><p>White opaque PVC/PE/PVDC-Aluminium foil blister in cardboard boxes.</p><p>Matever tablets are packaged in blister packs supplied in cardboard boxes containing:</p><ul><li><p>250 mg: 20, 30, 50, 60, 100 and multipack of 200 (2 packs of 100) film-coated tablets.</p></li><li><p>500 mg: 10, 20, 30, 50, 60, 100, 120 and multipack of 200 (2 packs of 100) film-coated tablets.</p></li><li><p>750 mg: 20, 30, 50, 60, 80, 100, 120 and multipack of 200 (2 packs of 100) film-coated tablets.</p></li><li><p>1000 mg: 10, 20, 30, 50, 60, 100 and multipack of 200 (2 packs of 100) film-coated tablets.</p></li></ul><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer</p><p>Marketing Authorisation Holder Pharmathen S.A., 6 Dervenakion Str., 15351 Pallini, Attiki, Greece</p><p>Manufacturer Pharmathen S.A. 6 Dervenakion Str. 15351 Pallini, Attiki Greece</p><p>or</p><p>Pharmathen International S.A. Industrial Park Sapes,<br/>Rodopi Prefecture, Block No 5,<br/>Rodopi 69300,<br/>Greece</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>Belgi /Belgique/Belgien Pharmathen S.A. T l/Tel: +30 210 66 04 Lietuva SIA ELVIM Tel: +371 67808<br/>Pharmathen S.A. Te .: +30 210 66 04 Luxembourg/Luxemburg Pharmathen S.A. Tel: +30 210 66 04 esk republika ARDEZ Pharma, spol. s r.o. Tel.: +420 220 400 Magyarorsz g<br/>Pharmathen S.A. Tel.: +30 210 66 04 Danmark Pharmathen S.A. Tel.: +30 210 66 04 Malta Pharmathen S.A. Tel: +30 210 66 04 Deutschland Pharmathen S.A. Tel.: +30 210 66 04 Nederland Pharmathen S.A. Tel: +30 210 66 04 Eesti (Estonia) SIA ELVIM Tel: +371 67808Norge Pharmathen S.A. Tlf: +30 210 66 04<br/>INNOVIS PHARMA<br/>: +30 210 66 64 805- sterreich<br/>Pharmathen S.A. Tel: +30 210 66 04 Espa a Pharmathen S.A. Tel: +30 210 66 04 Polska Pharmathen S.A. Tel.: +30 210 66 04 France Pharmathen S.A. T l: +30 210 66 04 Hrvatska Pharmathen S.A. Tel: +30 210 66 04 Portugal Pharmathen S.A. Tel: +30 210 66 04 Rom nia Pharmathen S.A. Tel: +30 210 66 04 Ireland Pharmathen S.A. Tel: +30 210 66 04 Slovenija Pharmathen S.A. Tel: +30 210 66 04 sland Alvogen ehf. Tel: +354 522 2Slovensk republika<br/>ARDEZ Pharma, spol. s r.o. Tel: +420 220 400 Italia Ecupharma S.r.l Tel : +39-02-38238Suomi/Finland Ailon Pharma Oy Puh/Tel: +358 407024<br/>The Star Medicines Importers Co. Ltd : +357 25371Sverige<br/>Pharmathen S.A. Tel: +30 210 66 04 Latvija<br/>SIA ELVIM Tel: +371 67808United Kingdom (Northern Ireland) Pharmathen S.A. Tel: +30 210 66 04 This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp26b20b6a67265be2cf1102bb12c87943",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp26b20b6a67265be2cf1102bb12c87943",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp26b20b6a67265be2cf1102bb12c87943\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp26b20b6a67265be2cf1102bb12c87943</b></p><a name=\"mp26b20b6a67265be2cf1102bb12c87943\"> </a><a name=\"hcmp26b20b6a67265be2cf1102bb12c87943\"> </a><a name=\"mp26b20b6a67265be2cf1102bb12c87943-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/11/711/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Matever 250 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/11/711/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Matever 250 mg film-coated tablets",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
